MAP kinase fragment [Multiple species]
(Synonyms: H2N-Lys-Tyr-Ile-His-Ser-Ala-Asn-Val-Leu-OH ) 目录号 : GP10140
Lys-Tyr-Ile-His-Ser-Ala-Asn-Val-Leu
![MAP kinase fragment [Multiple species] Chemical Structure](/media/struct/GP1/GP10140.png "MAP kinase fragment [Multiple species] Chemical Structure")
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
This Mitogen-activated protein kinase (MAP kinase) fragment has a peptide sequence of Lys-Tyr-Ile-His-Ser-Ala-Asn-Val-Leu.
The MAP kinases are serine/threonine-specific protein kinases belonging to the CMGC (CDK/MAPK/GSK3/CLK) kinase group.
MAPK pathways are a collection of protein signaling cascades stimulated by a wide variety of extracellular signals, including growth factors, cytokines and environmental stresses. Upon activation, MAPK pathways regulate many fundamental cellular functions, including differentiation, proliferation and apoptosis, through the activation of specific transcription factors and other regulatory proteins.
MAPKs are involved in directing cellular responses to a diverse array of stimuli, such as mitogens, osmotic stress, heat shock and proinflammatory cytokines. MAPK proteins have been repeatedly implicated in the pathogenesis of cancer and autoimmune diseases, leading to their selection as targets for drug development.
References:
1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (December 2002). "The protein kinase complement of the human genome". Science 298 (5600): 1912–34.
2. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH (April 2001). "Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions". Endocr. Rev. 22 (2): 153–83.
3. Bandyopadhyay S. et al. “A human MAP kinase interactome”. Nature Methods. 7(2010);801-805.
4. Chang, L. & Karin, M. Mammalian MAP kinase signalling cascades. Nature 410, 37–40 (2001).
5. Widmann, C., Gibson, S., Jarpe, M.B. & Johnson, G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 79, 143–180 (1999).
6. Kolch, W., Calder, M. & Gilbert, D. When kinases meet mathematics: the systems biology of MAPK signalling. FEBS Lett. 579, 1891–1895 (2005).
7. Johnson, G.L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911–1912 (2002).
| Cas No. | SDF | ||
| 别名 | H2N-Lys-Tyr-Ile-His-Ser-Ala-Asn-Val-Leu-OH | ||
| Canonical SMILES | NC(CCCCN)C(NC(CC1=CC=C(O)C=C1)C(NC(C(CC)C)C(NC(CC2=CN=CN2)C(NC(CO)C(NC(C)C(NC(CC(N)=O)C(NC(C(C)C)C(NC(CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O | ||
| 分子式 | C48H77N13O13 | 分子量 | 1044.2 |
| 溶解度 | ≥ 104.4mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9577 mL | 4.7884 mL | 9.5767 mL |
| 5 mM | 0.1915 mL | 0.9577 mL | 1.9153 mL |
| 10 mM | 0.0958 mL | 0.4788 mL | 0.9577 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet